Article (Scientific journals)
Fourth Belgian multicentre survey of antibiotic susceptibility of anaerobic bacteria
Wybo, Ingrid; Van den Bossche; Soetens, Oriane et al.
2014In Journal of Antimicrobial Chemotherapy, 69, p. 155-161
Peer Reviewed verified by ORBi
 

Files


Full Text
J. Antimicrob. Chemother.-2014-Wybo-155-61.pdf
Publisher postprint (188.37 kB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Anaerobes; Etest; Surveillance
Abstract :
[en] Objectives: To collect recent data on the susceptibility of anaerobes to antimicrobial agents with known activity against anaerobes, and to compare them with results from previous Belgian multicentre studies. Methods: Four hundred and three strict anaerobic clinical isolates were prospectively collected from February 2011 to April 2012 in eight Belgian university hospitals. MICs were determined by one central laboratory for 11 antimicro- bial agents using Etest methodology. Results: According to EUCAST breakpoints, .90% of isolates were susceptible to amoxicillin/clavulanate (94%), piperacillin/tazobactam (91%), meropenem (96%), metronidazole (92%) and chloramphenicol (98%), but only 70% and 40% to clindamycin and penicillin, respectively. At CLSI recommended breakpoints, only 71% were sus- ceptible to moxifloxacin and 79% to cefoxitin. MIC50/MIC90 values for linezolid and for tigecycline were 1/4 and 0.5/ 4 mg/L, respectively. When compared with survey data from 2004, no major differences in susceptibility profiles were noticed. However, the susceptibility of Prevotella spp. and other Gram-negative bacilli to clindamycin decreased from 91% in 1993 – 94 and 82% in 2004 to 69% in this survey. Furthermore, the susceptibility of clostridia to moxifloxacin decreased from 88% in 2004 to 66% in 2011 – 12 and that of fusobacteria from 90% to 71%. Conclusions: Compared with previous surveys, little evolution was seen in susceptibility, except a decline in activity of clindamycin against Prevotella spp. and other Gram-negative bacteria, and of moxifloxacin against clostridia. Since resistance was detected to all antibiotics, susceptibility testing of anaerobic isolates is indicated in severe infections to confirm appropriateness of antimicrobial therapy.
Disciplines :
Laboratory medicine & medical technology
Immunology & infectious disease
Author, co-author :
Wybo, Ingrid;  Vrije Universiteit Brussel - VUB > Department of Microbiology and Infection Control
Van den Bossche;  Vrije Universiteit Brussel - VUB > Department of Microbiology and Infection Control
Soetens, Oriane;  Vrije Universiteit Brussel - VUB > Department of Microbiology and Infection Control
Vekens, Evilien;  Vrije Universiteit Brussel - VUB > Department of Microbiology and Infection Control
Vandoorslaer, Kristof;  Vrije Universiteit Brussel - VUB > Department of Microbiology and Infection Control
Claeys, Geert;  Universitair Ziekenhuis Gent - UZ > Department of Microbiologyl
Glupczynski, Youri;  Université Catholique de Louvain - UCL > Department of Microbiology - Mont Godinne Dinant
Ieven, margareta;  Universitair Ziekenhuis Antwerpen - UZA > Medical microbiology
MELIN, Pierrette  ;  Centre Hospitalier Universitaire de Liège - CHU > Microbiologie médicale
Nonhoff, Claire;  Cliniques Universitaires de Bruxelles - Hôpital Erasme > Department of microbiology
Rodriguez-Villalobos, Hector;  Cliniques Universitaires Saint-Luc (Bruxelles) > Department of Microbiology
Verhaegen, Jan;  Universitair Ziekenhuis - KUL > Department of Clinical Microbiology
Pierard, Denis;  Vrije Universiteit Brussel - VUB > Department of Microbiology and Infection Control
More authors (3 more) Less
Language :
English
Title :
Fourth Belgian multicentre survey of antibiotic susceptibility of anaerobic bacteria
Publication date :
January 2014
Journal title :
Journal of Antimicrobial Chemotherapy
ISSN :
0305-7453
eISSN :
1460-2091
Publisher :
Oxford University Press, London, United Kingdom
Volume :
69
Pages :
155-161
Peer reviewed :
Peer Reviewed verified by ORBi
Funders :
This work was supported by grants from Bayer, Brussels, Pfizer, Brussels and AstraZeneca, Brussels.
Available on ORBi :
since 10 January 2014

Statistics


Number of views
79 (5 by ULiège)
Number of downloads
0 (0 by ULiège)

Scopus citations®
 
71
Scopus citations®
without self-citations
69
OpenCitations
 
62

Bibliography


Similar publications



Contact ORBi